Prevention of Alzheimer's disease in high risk groups: Statin therapy in subjects with PSEN1 mutations or heterozygosity for apolipoprotein e epsilon 4

Alzheimer's Research and Therapy

Volumn 2, Issue 5, 2010, Pages

  Pollen, Daniel A ^a   Baker, Stephen ^a   Hinerfeld, Douglas ^b   Swearer, Joan ^a   Evans, Barbara A ^a   Evans, James E ^a   Caselli, Richard ^c   Rogaeva, Ekaterina ^d   St George Hyslop, Peter ^d,e,f   Moonis, Majaz ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b JACKSON LABORATORY   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e TORONTO WESTERN HOSPITAL   (Canada)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

24 HYDROXYCHOLESTEROL; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AMYLOID PRECURSOR PROTEIN ALPHA; APOLIPOPROTEIN E4; APOLIPOPROTEIN EEPSILON4; ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LATHOSTEROL; PRAVASTATIN; PRESENILIN 1; SIMVASTATIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GENE MUTATION; HETEROZYGOSITY; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; INTERVENTION STUDY; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; REVIEW; RISK REDUCTION; TREATMENT OUTCOME;

EID: 78149359327     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt55     Document Type: Review

References (56)

1. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. R Sherrington El Rogaev Y Liang EA Rogaeva G Levesque M Ikeda H Chi C Lin G Li K Holman,, et al. Nature 1995 375 754 760 10.1038/375754a0 7596406
2. A beta oligomers - a decade of discovery. DJ Selkoe, J Neurochem 2007 101 1172 1184 10.1111/j.1471-4159.2006.04426.x 17286590
3. How do soluble oligomers of amyloid beta-protein impair hippocampal synaptic plasticity? S Li GM Shankar DJ Selkoe, Front Cell Neurosci 2010 4 5 20428510
4. Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. M Moonis JM Swearer MP Dayaw P St George-Hyslop E Rogaeva T Kawarai DA Pollen, Neurology 2005 65 323 325 10.1212/01.wnl.0000171397.32851.bc 16043812
5. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. EC Petrie DJ Cross D Galasko GD Schellenberg MA Raskind ER Peskind S Minoshima, Arch Neurol 2009 66 632 637 10.1001/archneurol.2009.59 19433663
6. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. B Wolozin W Kellman P Ruosseau GG Celesia G Siegel, Arch Neurol 2000 57 1439 1443 10.1001/archneur.57.10.1439 11030795
7. Statins and the risk of dementia. H Jick GL Zornberg SS Jick S Seshadri DA Drachman, Lancet 2000 356 1627 1631 10.1016/S0140-6736(00)03155-X 11089820
8. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. MD Haag A Hofman PJ Koudstaal BH Stricker MM Breteler, J Neurol Neurosurg Psychiatry 2009 80 13 17 10.1136/jnnp.2008.150433 18931004
9. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. C Cramer MN Haan S Galea KM Langa JD Kalbfleisch, Neurology 2008 71 344 350 10.1212/01.wnl.0000319647.15752.7b 18663180
10. Reduced risk of incident AD with elective statin use in a clinical trial cohort. DL Sparks RJ Kryscio MN Sabbagh DJ Connor LM Sparks C Liebsack, Curr Alzheimer Res 2008 5 416 421 10.2174/156720508785132316 18690839
11. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20,536 high-rsk individuals: a randomized placebo controlled trial. Heart Protection Study Collaborative Group, Lancet 2002 360 7 22 10.1016/S0140- 6736(02)09327-3 12114036
12. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. PP Zandi DL Sparks AS Khachaturian J Tschanz M Norton M Steinberg KA Welsh-Bomer JC Breitner, Arch Gen Psychiatry 2005 62 217 224 10.1001/archpsyc.62.2.217 15699299
13. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Z Arvanitakis JA Schneider RS Wilson JL Bienias JF Kelly DA Evans DA Bennett, Neurology 2008 70 1795 1802 10.1212/01.wnl.0000288181.00826.63 18199831
14. Statins and cognitive function. L Sparks, J Neurol Neurosurg Psychiatry 2009 80 1 10.1136/jnnp.2008.160291 19091701
15. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate -amyloid-induced microglial inflammatory responses. A Cordle G Landreth, J Neurosci 2005 25 299 307 10.1523/JNEUROSCI.2544-04.2005 15647473
16. Prevention of stroke and dementia by statin therapy: experimental and clinical evidence of their pleiotropic effects. T Miida A Takahashi T Ikeuchi, Pharmacol Ther 2007 113 378 393 10.1016/j.pharmthera.2006.09.003 17113151
17. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. E Kojro G Gimpl S Lammich W Marz F Fahrenholz, Proc Natl Acad Sci USA 2001 98 5815 5820 10.1073/pnas.081612998 11309494
18. Statins differentially affect amyloid precursor protein metabolism in presymptomatic PS1 and non-PS1 subjects. DA Hinerfeld M Moonis JM Swearer SP Baker RJ Caselli E Rogaeva P St George-Hyslop DA Pollen, Arch Neurol 2007 64 1672 1673 10.1001/archneur.64.11.1672 17998454
19. Long-term statin therapy and CSF cholesterol levels: implications for Alzheimer's disease. BA Evans JE Evans SP Baker K Kane J Swearer D Hinerfeld R Caselli E Rogaeva P St George-Hyslop M Moonis DA Pollen, Dement Geriatr Cogn Disord 2009 27 519 524 10.1159/000221835 19478483
20. DA Pollen, The Quest for the Genetic Origins of Alzheimer's Disease Oxford University Press 1996
21. Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: opportunities and challenges. JM Ringman J Grill Y Rodriguez-Agudelo M Chavez C Xiong, Alzheimers Dement 2009 5 166 171 10.1016/j.jalz.2008.12.002 19328453
22. Processing of the -Amyloid precursor protein and it regulation in Alzheimer's disease. F Checler, J Neurochem 1995 65 1431 1444 10.1046/j.1471-4159.1995.65041431.x 7561836
23. Regulation of amyloid precursor protein cleavage. J Mills PB Reiner, J Neurochem 1999 72 443 460 10.1046/j.1471-4159.1999.0720443.x 9930716
24. Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer's disease. K Hoglund S Syversen P Lewczuk A Wallin J Wiltfang K Blennow, Exp Brain Res 2005 164 205 214 10.1007/s00221-005-2243-8 15937702
25. Trophic effect of beta-amyloid precursor protein on cerebral cortical neurons in culture. W Araki N Kitaguchi Y Tokushima K Ishii H Aratake S Shimohama S Nakamurua J Kimura, Biochem Biophys Res Commun 1991 181 265 271 10.1016/S0006-291X(05)81412-3 1958195
26. A heparin-binding domain in the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neurite outgrowth. DH Small V Nurcombe G Reed H Clarris R Moir K Beyreuther CL Masters, J Neurosci 1994 14 2117 2127 8158260
27. Involvement of amyloid precursor protein in function synapse formation in cultured hippocampal neurons. T Morimoto I Ohsawa C Takamura M Ishiguro S Kohsaka, J Neurosci Res 1998 51 185 195 10.1002/(SICI)1097-4547(19980115)51: 2<185::AID-JNR73.0.CO;2-9 9469572
28. + channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein. K Furukawa SW Barger EM Blalock MP Mattson, Nature 1996 379 74 78 10.1038/379074a0 8538744
29. Secreted beta-amyloid precursor protein counteracts the proapoptotic action of mutant presenilin-1 by activation of NF-kappaB and stabilization of calcium homeostatsis. Q Guo N Robinson MP Mattson, J Biol Chem 1998 273 12341 12351 10.1074/jbc.273.20.12341 9575187
30. Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice. H Meziane JC Dodart C Mathis S Little J Clemens SM Paul A Ungerer, Proc Natl Acad Sci USA 1998 95 12683 12688 10.1073/pnas.95.21.12683 9770546
31. Treatment with simvastatin in normo-cholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. M Simons F Schwärzler D Lütjohann K von Bergmann K Beyreuther J Dichgans H Wormstall T Hartmann JB Schulz, Ann Neurol 2002 52 346 350 10.1002/ana.10292 12205648
32. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid disease -amyloid peptides A42 and A40 in vitro and in vivo. K Fassbender M Simons C Bergmann M Stroick D Lutjohann P Keller H Runz S Kuhl T Bertsch K von Bergmann M Hennerici K Beyreuther T Hartmann, Proc Natl Acad Sci USA 2001 98 5856 5861 10.1073/pnas.081620098 11296263
33. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. RG Riekse G Li EC Petrie JB Leverenz D Vavrek S Vuletic JJ Albers TJ Montine VM Lee M Lee P Seubert D Galasko GD Schellenberg WR Hazzard ER Peskind, J Alzheimers Dis 2006 10 399 406 17183151
34. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. G Li EB Larson JA Sonnen JB Shofer EC Petrie A Schantz ER Peskind MA Raskind JC Breitner TJ Montine, Neurology 2007 69 878 885 10.1212/01.wnl.0000277657.95487.1c 17724290
35. Oxidative stress in vascular dementia and Alzheimer's disease: a common pathology. S Bennett MM Grant S Aldred, J Alzheimers Dis 2009 17 245 257 19221412
36. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. P Agostinho RA Cunha C Oliveira, Curr Pharm Des 2010 16 2766 2778 20698820
37. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. J Laurén DA Gimbel HB Nygaard JW Gilbert SM Strittmatter, Nature 2009 457 1128 1132 10.1038/nature07761 19242475
38. Cellular prion protein mediates the toxicity of beta-amyloid oligomers: implications for Alzheimer disease. HB Nygaard SM Strittmatter, Arch Neurol 2009 66 1325 1328 10.1001/archneurol.2009.223 19901162
39. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. DA Gimbel HB Nygaard EE Coffey EC Gunther J Laurén ZA Gimbel SM Strittmatter, J Neurosci 2010 30 6367 6374 10.1523/JNEUROSCI.0395-10.2010 20445063
40. The prion protein as a receptor for amyloid-beta. HW Kessels LN Nguyen S Nabavi R Malinow, Nature 2010 466 3 4 10.1038/nature09217 20703260
41. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. C Balducci M Beeg M Stravalaci A Bastone A Sclip E Biasini L Tapella L Columbo C Manzoni T Borsello R Chiesa M Gobbi M Salmona G Forloni, Proc Natl Acad Sci USA 2010 107 2295 2300 10.1073/pnas.0911829107 20133875
42. Prion protein and Abeta-related synaptic toxicity impairment. AM Calella M Farinelli M Nuvolone O Mirante R Moos J Falsig IM Mansuy A Aguzzi, EMBO Mol Med 2010 2 306 314 10.1002/emmm.201000082 20665634
43. Regulation of betaAPP and PrPc cleavage by alpha-secretase: mechanistic and therapeutic perspectives. B Vincent MA Cisse C Sunyach MV Guillot-Sestier F Checler, Curr Alzheimer Res 2008 5 202 211 10.2174/156720508783954749 18393805
44. The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity. MA Cissé C Sunyach S Lefranc-Jullien R Postina B Vincent F Checler, J Biol Chem 2005 280 40624 40631 10.1074/jbc.M506069200 16236709
45. Alzheimer's disease: A prion protein connection. M Cisse L Mucke, Nature 2009 457 1090 1091 10.1038/4571090a 19242462
46. Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides. GK Gouras H Xu RS Gross JP Greenfield B Hai R Wang P Greengard, Proc Natl Acad Sci USA 2000 97 1202 1205 10.1073/pnas.97.3.1202 10655508
47. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. H Xu GK Gouras JP Greenfield B Vincent J Naslund L Mazzarelli G Fried JN Jovanovic M Seeger NR Relkin F Liao F Checler JD Buxbaum BT Chait G Thinakaran SS Sisodia R Wang P Greengard S Gandy, Nat Med 1998 4 447 451 10.1038/nm0498-447 9546791
48. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. A Solomon M Kivipelto B Wolozin J Zhou RA Whitmer, Dement Geriatr Cogn Disord 2009 28 75 80 10.1159/000231980 19648749
49. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. JH Lee WH Yu A Kumar S Lee PS Mohan CM Peterhoff DM Wolfe M Martinez-Vicente AC Massey G Sovak Y Uchiyama D Westaway AM Cuervo RA Nixon, Cell 2010 141 1146 1158 10.1016/j.cell.2010.05.008 20541250
50. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. A Fire S Xu MK Montgomery SA Kostas SE Driver CC Mello, Nature 1998 391 806 811 10.1038/35888 9486653 (Pubitemid 28099681)
51. The evolution of our thinking about microRNAs. V Ambros, Nat Med 2008 14 1036 1040 10.1038/nm1008-1036 18841144
52. The Caenorhabditis elegans heterochronic gene lin-14 encodes a nuclear protein that forms a temporal developmental switch. G Ruvkun J Giusto, Nature 1989 338 313 319 10.1038/338313a0 2922060
53. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. DL Sparks DJ Connor MN Sabbagh RB Peterson J Lopez P Browne, Acta Neurol Scand Suppl 2006 185 3 7 10.1111/j.1600-0404.2006.00690.x 16866904
54. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. HH Feldman RS Doody M Kivipelto DL Sparks DD Waters RW Jones E Schwam R Schindler J Hey-Hadavi DA DeMicco A Breazna LEADe Investigators, Neurology 2010 74 956 964 10.1212/WNL.0b013e3181d6476a 20200346
55. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. S Trompet P van Vliet AJ de Craen J Jolles BM Buckley MB Murphy I Ford PW Macfarlane N Sattar CJ Packard DJ Stott J Shepherd EL Bollen GJ Blauw JW Jukema RG Westendorp, J Neurol 2010 257 85 90 10.1007/s00415-009-5271-7 19653027
56. Statins for the prevention of dementia. B McGuinness D Craig R Bullock P Passmore, Cochrane Database Syst Rev 2009 D003160 19370582